Loading patent…
AssigneeMammoth Biosciences, Inc.
InventorsBenjamin Julius RAUCH, Aaron DELOUGHERY, Matan DRORY RETWITZER, David PAEZ-ESPINO, Caleb TRECAZZI, Lucas Benjamin HARRINGTON, Janice Sha CHEN, James Paul BROUGHTON, Clarissa Oriel RHINES, William Douglass WRIGHT, Matthew VEROSLOFF, Carley Gelenter HENDRIKS
Estimating the term…
The present disclosure provides compositions and methods of use for a Type VI CRISPR/Cas nuclease. Type VI CRISPR/Cas nucleases are able to bind to a target nucleic acid, thereby activating trans-collateral nuclease activity on nucleic acid reports. Furthermore, the present disclosure provides methods to modify ribonucleic acid sequences using the programmable nucleases disclosed herein.
A non-naturally occurring composition comprising a programmable nuclease and an engineered guide nucleic acid, wherein the programmable nuclease comprises an amino acid sequence that is at least 75% identical to any one of SEQ ID NOs:
-16. (canceled)
-24. (canceled)
(canceled)
A non-naturally occurring composition comprising a programmable nuclease and an engineered guide nucleic acid capable of catalyzing cRNA-directed, RNA-targeted trans-cleavage activity at a temperature of at least about 55° C. to at least about 85° C., wherein the programmable nuclease comprises at least one HEPN or HEPN-like domain.
(canceled)
A non-naturally occurring composition comprising a programmable nuclease comprising at least one HEPN or HEPN-like domain and an engineered guide nucleic acid capable of catalyzing at least a 1.5 fold change in cRNA-directed, RNA-targeted trans-cleavage activity.
-39. (canceled)
-49. (canceled)
-54. (canceled)
-66. (canceled)
-173. (canceled)
A method of detecting a nucleic acid in a sample, comprising the steps of:
-200. (canceled)
-256. (canceled)
Dependencies are inferred from the claim text.